Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Mogamulizumab Hits Primary Endpoint in PIII for CTCL: Kyowa Kirin
April 10, 2017
- Kyowa Kirin’s KRN23 Delivers Positive PII Data for Pediatric X-Linked Hypophosphatemia
April 10, 2017
- Takeda-PRA Joint Venture in Japan to Be Formed on June 1
April 10, 2017
- Trerief Delivers Positive Results in Lewy Body Dementia: Sumitomo Dainippon
April 7, 2017
- Boehringer Japan to Spur Joint Drug Discovery Research, Eyes 1st Clinical Trial in 2020
April 7, 2017
- Takeda Earns Global Rights to Finch’s Microbiome IBD Therapy
April 7, 2017
- Takeda’s Massive Dengue Trial Enrollment Completed
April 7, 2017
- Heptares Gains Preclinical Milestone in AZ Immuno-Oncology Deal
April 6, 2017
- Eisai Gets Japan, Asian Rights to Safinamide from Meiji
April 6, 2017
- Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility
April 6, 2017
- Mochida Aims for Sales of 107 Billion Yen in FY2017 under New 3 Year Biz Plan
April 5, 2017
- Daiichi Sankyo Sells US Packaging Plant
April 5, 2017
- Bayer Yakuhin Running Pilot AI Program for Sales Rep Support
April 5, 2017
- MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
April 5, 2017
- AstraZeneca Transfers 5 Anesthetic Brands to Aspen in Japan under Global Deal
April 4, 2017
- Astellas Acquires Belgium Drug Firm Ogeda
April 4, 2017
- Takeda Consumer Healthcare Spin-Off Now Up and Running
April 4, 2017
- Pfizer Introduces Further Voluntary Recall of EpiPen 0.3 mg in Japan
April 4, 2017
- Alcon Pharma Kicks Off Operations
April 3, 2017
- Pfizer Joins Japan Biosimilar Association
April 3, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…